Karyopharm Therapeutics (KPTI) Tops Q3 EPS by 12c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.69), $0.12 better than the analyst estimate of ($0.81).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Danone SA (BN:FP) (DANOY) PT Raised to EUR63 at Deutsche Bank